Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jun 19;309(23):2473-9.
doi: 10.1001/jama.2013.6285.

Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children

Anette G Ziegler  1 , Marian Rewers, Olli Simell, Tuula Simell, Johanna Lempainen, Andrea Steck, Christiane Winkler, Jorma Ilonen, Riitta Veijola, Mikael Knip, Ezio Bonifacio, George S Eisenbarth
Affiliations

Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children

Anette G Ziegler et al. JAMA. .

Abstract

Importance: Type 1 diabetes usually has a preclinical phase identified by circulating islet autoantibodies, but the rate of progression to diabetes after seroconversion to islet autoantibodies is uncertain.

Objective: To determine the rate of progression to diabetes after islet autoantibody seroconversion.

Design, setting, and participants: Data were pooled from prospective cohort studies performed in Colorado (recruitment, 1993-2006), Finland (recruitment, 1994-2009), and Germany (recruitment, 1989-2006) examining children genetically at risk for type 1 diabetes for the development of insulin autoantibodies, glutamic acid decarboxylase 65 (GAD65) autoantibodies, insulinoma antigen 2 (IA2) autoantibodies, and diabetes. Participants were all children recruited and followed up in the 3 studies (Colorado, 1962; Finland, 8597; Germany, 2818). Follow-up assessment in each study was concluded by July 2012.

Main outcomes and measures: The primary analysis was the diagnosis of type 1 diabetes in children with 2 or more autoantibodies. The secondary analysis was the diagnosis of type 1 diabetes in children with 1 autoantibody or no autoantibodies.

Results: Progression to type 1 diabetes at 10-year follow-up after islet autoantibody seroconversion in 585 children with multiple islet autoantibodies was 69.7% (95% CI, 65.1%-74.3%), and in 474 children with a single islet autoantibody was 14.5% (95% CI, 10.3%-18.7%). Risk of diabetes in children who had no islet autoantibodies was 0.4% (95% CI, 0.2%-0.6%) by the age of 15 years. Progression to type 1 diabetes in the children with multiple islet autoantibodies was faster for children who had islet autoantibody seroconversion younger than age 3 years (hazard ratio [HR], 1.65 [95% CI, 1.30-2.09; P < .001]; 10-year risk, 74.9% [95% CI, 69.7%-80.1%]) vs children 3 years or older (60.9% [95% CI, 51.5%-70.3%]); for children with the human leukocyte antigen (HLA) genotype DR3/DR4-DQ8 (HR, 1.35 [95% CI, 1.09-1.68; P = .007]; 10-year risk, 76.6% [95% CI, 69.2%-84%]) vs other HLA genotypes (66.2% [95% CI, 60.2%-72.2%]); and for girls (HR, 1.28 [95% CI, 1.04-1.58; P = .02];10-year risk, 74.8% [95% CI, 68.0%-81.6%]) vs boys (65.7% [95% CI, 59.3%-72.1%]).

Conclusions and relevance: The majority of children at risk of type 1 diabetes who had multiple islet autoantibody seroconversion progressed to diabetes over the next 15 years. Future prevention studies should focus on this high-risk population.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Development of Diabetes in Children Stratified for Islet Autoantibody Outcome The numbers at risk represent the children receiving follow-up at age 0, 5, 10, 15, and 20 years.
Figure 2
Figure 2
Progression to Diabetes From the Time of Seroconversion in Children With Multiple Islet Autoantibodies
Figure 3
Figure 3
Progression to Diabetes in Children From the Time of Seroconversion According to Islet Autoantibody Type IAA indicates insulin autoantibodies; IA2, insulinoma antigen 2 autoantibodies; and GAD65, glutamic acid decarboxylase 65 autoantibodies. The numbers at risk represent the children receiving follow-up at year 0, 5, 10, and 15.
See this image and copyright information in PMC

Comment in

  • The evolution of type 1 diabetes.
    Skyler JS, Sosenko JM. Skyler JS, et al. JAMA. 2013 Jun 19;309(23):2491-2. doi: 10.1001/jama.2013.6286. JAMA. 2013. PMID: 23780463 No abstract available.

References

    1. Eisenbarth GS. Type I diabetes mellitus: a chronic autoimmune disease. N Engl J Med. 1986;314(21):1360–1368. - PubMed
    1. Milton B, Holland P, Whitehead M. The social and economic consequences of childhood-onset type 1 diabetes mellitus across the lifecourse: a systematic review. Diabet Med. 2006;23(8):821–829. - PubMed
    1. Tarn AC, Thomas JM, Dean BM, et al. Predicting insulin-dependent diabetes. Lancet. 1988;1(8590):845–850. - PubMed
    1. Gale EA, Bingley PJ, Emmett CL, Collier T. European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet. 2004;363(9413):925–931. - PubMed
    1. Diabetes Prevention Trial—Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med. 2002;346(22):1685–1691. - PubMed

Publication types

MeSH terms